Abbott reports third-quarter 2024 results and raises midpoint of full-year eps guidance range

Sales of $10.6 billion driven by strong underlying base business performance reported sales growth of 4.9 percent; organic sales growth for underlying base business of 8.2 percent1, led by double-digit growth in medical devices continues to strengthen portfolio with steady cadence of new product approvals, reimbursement coverage, and clinical data abbott park, ill., oct. 16, 2024 /prnewswire/ -- abbott (nyse: abt) today announced financial results for the third quarter ended sept.
ABT Ratings Summary
ABT Quant Ranking